Xencor Inc (XNCR): R&D Expense
$239.43M
Year ended 2025-12-31
$255.76M
Trailing 12 months to 2026-06-30
+6.3%
3-year compound annual growth
+7.1%
5-year compound annual growth
+21.5%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $239.43M | +5.2% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $227.69M | -10.2% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $253.60M | +27.1% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $199.56M | +3.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $192.51M | +13.4% | 2025-02-24, From 2021-01-01 |
| 2020-12-31 | $169.80M | +43.2% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $118.59M | +21.6% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $97.50M | +35.8% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $71.77M | +38.4% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $51.87M | +51.9% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $34.14M | +84.4% | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | $18.52M | +8.9% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $17.00M | +34.2% | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $12.67M | n/a | 2015-02-23, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Xencor Inc (XNCR) | 2025-12-31 | $239.43M | +5.2% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.26M | -3.7% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.70M | +13.9% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $67.11M | +17.4% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $125.62M | -12.3% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $37.41M | -0.6% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $12.74M | -69.7% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $137.00M | +1.8% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $5.74M | -27.9% |
Compare XNCR, LFCR, GYRE, URGN side by side · Screen every company in Pharmaceutical Preparations ↗